---
title: "Oxygenta Pharmaceutical Ltd (524636) — Share Price, Financials & Analysis"
symbol: "524636"
company: "Oxygenta Pharmaceutical Ltd"
canonical: "https://tapetide.com/stocks/524636"
isin: "INE102E01018"
nse_symbol: "OXYGENTAPHLTD"
bse_code: "524636"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 194.23
generated_at: "2026-09-13T18:47:59.084Z"
---

# Oxygenta Pharmaceutical Ltd (524636)

Canonical page: https://tapetide.com/stocks/524636

## Company

- **NSE Symbol:** OXYGENTAPHLTD
- **BSE Code:** 524636
- **ISIN:** INE102E01018
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 1997-10-20
- **CEO:** Mr. Prasad Reddy Battinapatla
- **Employees:** 175
- **Face Value:** ₹10
- **F&O Eligible:** No
- **Website:** oxygentapharma.com

## About

Incorporated in 1990, Oxygenta Pharmaceutical Ltd manufactures Bulk Drugs and API including Pharmaceutical preparation, and Organic Fine Chemicals.

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:35:37.331343Z.

- **Market Cap:** ₹194.23 Cr
- **Classification:** Microcap
- **P/E (reported):** -14.7
- **EPS (TTM):** ₹-3.67
- **EPS (reported):** ₹0
- **Book Value:** ₹-11.54
- **Price to Book:** -4.66
- **Dividend Yield:** 0%
- **ROE:** 41.16%
- **ROCE:** -51.82%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹113.3 Cr
- **Net Income:** ₹-17.6 Cr
- **EBITDA:** ₹-15.1 Cr
- **52-Week High:** ₹75
- **52-Week Low:** ₹43
- **RSI (14):** 42.42

## Tapetide Score

- **Score:** 38 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 10.2 (of 4473 scored stocks)
- **Confidence:** 84%
- **Data coverage:** 67%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 13.84 | 9% |
| growth | 67.13 | 9% |
| momentum | 67.42 | 12% |
| ownership | 50 | 24% |
| quality | 12.82 | 22% |
| valuation | 27.52 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is expected to give good quarter
- Company's median sales growth is 22.1% of last 10 years

### Weaknesses

- Company has low interest coverage ratio.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | — | -112.64% | — |
| ebitda margin growth | 100% | 67.84% | -45.29% | -643.27% |
| net income growth | -23.53% | 70.87% | -28% | — |
| revenue growth | -25.7% | 2.44% | 54% | 17% |
| roce | — | -112.73% | 24.51% | 53.87% |
| roe | — | 2.49% | 32.87% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 13.08 | 9.15 | 10.55 | 12.62 | 14.01 | 33.21 | 49.47 | 15.13 | 14.3 | 33.93 | 49.61 | 37 |
| Expenses | 15.06 | 11.63 | 12.17 | 14.4 | 16.18 | 37.57 | 51.15 | 21.96 | 18.87 | 38.01 | 49.49 | 36.45 |
| Operating Profit | -1.98 | -2.48 | -1.62 | -1.78 | -2.17 | -4.36 | -1.68 | -6.83 | -4.57 | -4.08 | 0.12 | 0.55 |
| OPM % | -15.14 | -27.1 | -15.36 | -14.1 | -15.49 | -13.13 | -3.4 | -45.14 | -31.96 | -12.02 | 0.24 | 1.49 |
| Other Income | -0.03 | -0.02 | 0.26 | 0.02 | 0.75 | 0.49 | -0.22 | 0.16 | -0.06 | 0 | 0.17 | 0.02 |
| Interest | 0.34 | 0.36 | 0.59 | 0.41 | 0.69 | 0.39 | 2.13 | 0.63 | 0.95 | 1.39 | 1.81 | 2.46 |
| Depreciation | 0.83 | 0.69 | 0.64 | 0.65 | 0.66 | 0.71 | -0.23 | 0.85 | 0.86 | 0.86 | -0.24 | 0.62 |
| Profit before tax | -3.18 | -3.55 | -2.59 | -2.82 | -2.77 | -4.97 | -3.8 | -8.15 | -6.44 | -6.33 | -1.28 | -2.51 |
| Tax % | -0.63 | 6.48 | -409.27 | -51.42 | 2.89 | -20.72 | -43.42 | -25.03 | -23.45 | -23.38 | 32.81 | -15.94 |
| Net Profit | -3.16 | -3.78 | 8.02 | -1.36 | -2.85 | -3.93 | -2.15 | -6.11 | -4.93 | -4.84 | -1.7 | -2.1 |
| EPS in Rs | -0.94 | -1.13 | 2.4 | -0.38 | -0.8 | -1.06 | -0.58 | -1.65 | -1.33 | -1.31 | -0.46 | -0.57 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 13 | 21 | 14 | 52 | 61 | 31 | 40 | 109 | 113 | 135 |
| Expenses | 17 | 23 | 22 | 48 | 59 | 38 | 49 | 119 | 128 | 143 |
| Operating Profit | -4 | -2 | -8 | 4 | 1 | -7 | -10 | -10 | -15 | -8 |
| OPM % | -31 | -10 | -57 | 7 | 2.4 | -23 | -24 | -9 | -14 | -6 |
| Other Income | 1 | 0 | 4 | 2 | 1 | -1 | 0 | 1 | 0 | 0 |
| Interest | 1 | 1 | 1 | 2 | 1 | 1 | 2 | 2 | 5 | 7 |
| Depreciation | 1 | 1 | 1 | 1 | 2 | 2 | 3 | 4 | 2 | 2 |
| Profit before tax | -4 | -3 | -6 | 3 | 0 | -11 | -14 | -14 | -22 | -17 |
| Tax % | 1 | -7 | -3 | 7 | 24 | 2 | -75 | -28 | -21 | — |
| Net Profit | -5 | -3 | -6 | 3 | -1 | -12 | -3 | -10 | -18 | -14 |
| EPS in Rs | -4.44 | -3.19 | -5.68 | 2.87 | -0.43 | -8.15 | -1.04 | -2.79 | -4.75 | -3.67 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 10 | 10 | 10 | 10 | 10 | 14 | 14 | 33 | 37 | 37 |
| Reserves | -38 | -42 | -45 | -51 | -48 | -49 | -60 | -54 | -63 | -80 |
| Borrowings | 19 | 19 | 22 | 27 | 48 | 52 | 68 | 57 | 62 | 110 |
| Other Liabilities | 27 | 30 | 34 | 33 | 24 | 14 | 32 | 26 | 46 | 53 |
| Total Liabilities | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |
| Fixed Assets | 12 | 12 | 12 | 11 | 16 | 20 | 28 | 29 | 37 | 48 |
| CWIP | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 6 | 5 | 9 | 7 | 17 | 11 | 26 | 34 | 46 | 72 |
| Total Assets | 19 | 17 | 21 | 19 | 34 | 31 | 54 | 63 | 83 | 120 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 1 | 1 | -8 | -3 | -2 | -2 | -2 | -13 | 3 | -28 |
| Cash from Investing Activity | -1 | 0 | -1 | 0 | -7 | -5 | -10 | -4 | -11 | -14 |
| Cash from Financing Activity | 0 | -1 | 8 | 3 | 9 | 6 | 11 | 17 | 8 | 43 |
| Net Cash Flow | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free Cash Flow | 0 | 1 | -8 | -3 | -8 | -7 | -11 | -17 | -8 | -41 |
| CFO/OP | -13 | -33 | 396 | 35 | -37 | -106 | 23 | 135 | -29 | 182 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 39 | 14 | 9 | 11 | 11 | 10 | 120 | 68 | 17 | 32 |
| Inventory Days | 122 | 57 | 121 | 100 | 121 | 56 | 178 | 149 | 78 | 105 |
| Days Payable | 599 | 396 | 203 | 190 | 137 | 50 | 362 | 249 | 113 | 174 |
| Cash Conversion Cycle | -439 | -325 | -73 | -79 | -5 | 16 | -64 | -32 | -18 | -37 |
| Working Capital Days | -512 | -438 | -164 | -275 | -14 | 8 | -94 | -89 | -184 | -119 |
| ROCE % | — | — | — | — | — | -1 | -47 | -42 | -33 | -34 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 29.73% | 29.73% | 29.73% | 33.69% | 53.28% | 51.12% | 51.12% | 57.95% | 57.95% | 55.93% | 56.54% | 56.54% |
| FIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| DIIs | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% | 0.03% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 53.65% | 53.17% | 53.31% | 50.3% | 41.81% | 43.93% | 43.93% | 36.61% | 36.55% | 38.9% | 38.12% | 38.16% |
| Others | 16.6% | 17.08% | 16.94% | 15.98% | 4.89% | 4.93% | 4.93% | 5.41% | 5.47% | 5.14% | 5.32% | 5.27% |
| No. of Shareholders | 8972 | 9051 | 10102 | 9975 | 10154 | 10111 | 10030 | 10094 | 10179 | 10215 | 10205 | 10196 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Buy
- **Buy / Neutral / Sell:** 8 / 6 / 5

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 55.05 | Buy |
| EMA (10) | 55.68 | Buy |
| SMA (20) | 58.81 | Sell |
| EMA (20) | 56.61 | Sell |
| SMA (50) | 54.59 | Buy |
| EMA (50) | 55.52 | Buy |
| SMA (100) | 53.26 | Buy |
| EMA (100) | 54.63 | Buy |
| SMA (200) | 54.04 | Buy |
| EMA (200) | 58.08 | Sell |

### Oscillators — summary: **Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 48.23 | Neutral |
| MACD (12,26,9) | -0.6 | Sell |
| Stochastic (14,3,3) | 16.03 | Buy |
| ADX (14) | 14.55 | Neutral |
| Williams %R (14) | -67.72 | Neutral |
| ATR (14) | 3.18 | High Volatility |
| ROC (12) | -7.42 | Sell |
| Stoch RSI (14) | 52.29 | Neutral |
| UO (7,14,28) | 37.04 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-08-21 | [Shareholder Meeting / Postal Ballot-Outcome of AGM](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=71f3b176-8153-4b6f-bddd-8503a3fc0b1d.pdf) |
| 2026-08-21 | [Shareholder Meeting / Postal Ballot-Scrutinizers Report](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=276b9546-3772-4cf8-9a5b-708cc557ae64.pdf) |
| 2026-07-31 | [Newspaper Advertisement](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=62a35910-acf5-4581-aa6f-84e90d2d81bd.pdf) |
| 2026-07-30 | [Submission Of Notice Of 33Rd Annual General Meeting For The Finanical Year 2025-26.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a269c95-e426-46f0-908d-01776bcf7752.pdf) |
| 2026-07-30 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cddccb0e-0a8d-44a5-ade7-ce800035f359.pdf) |
| 2026-07-30 | [Intimation Of Book Closure And Cut-Off Date For The 33Rd Annual General Meeting Of Oxygenta Pharmaceutical Limited.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=232b00f6-393e-4e80-b11b-f61fb361f815.pdf) |
| 2026-07-27 | [Board Meeting Outcome for Outcome For The Board Meeting Held On 27.07.2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a918cc5-d6cf-4e04-9d86-2c297e3f374f.pdf) |
| 2026-07-27 | [Announcement under Regulation 30 (LODR)-Change in Management](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=fbca9043-3f96-4887-9cb3-1153c03aba2a.pdf) |
| 2026-07-24 | [Update on board meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=82c354ac-0f42-45f1-9cad-f171cd572c95.pdf) |
| 2026-07-22 | [Board Meeting Intimation for The Meeting To Be Held On Saturday 25Th Day Of July 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d3074885-5690-4b59-8bae-eb4225998fc6.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-07-27 | [Un-Audited Results For The Quarter Ended 30.06.2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=82ef5e81-378b-40a4-83a9-c3063599bfbe.pdf) |
| 2026-05-23 | [Audited Financial Results For The Quarter And Year Ended 31.03.2026.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4d1a5b66-c650-46ee-9393-71b1deaa3c25.pdf) |
| 2026-02-04 | [Un-Audited Results For The Quarter And Nine Months Ended 31.12.2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f1e823da-80e2-4519-9e48-3d18d3ab06c0.pdf) |
| 2025-11-07 | [Un Audited Financial Results For The Quarter And Half Year Ended 30.09.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1ec6f776-0b6f-4ad2-af33-1b146b7cc7de.pdf) |
| 2025-08-14 | [Quarterly Results For The Quarter Ended 30.06.2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=23a832cd-85eb-4a16-b19e-c71e4574c27c.pdf) |
| 2025-05-30 | [Results For The Financial Year Ended 31St March 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8163e5f1-ba6c-4b0f-9924-f6862d4bfcb0.pdf) |
| 2025-02-14 | [Un Audited Financial Results For The Quarter Ended December 312024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6826eacf-6832-4421-88ed-688b2ac82455.pdf) |
| 2024-11-14 | [Un Audited Results For Quarter Ended On September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f5507b3-c3db-4991-81c5-1a9ddd96bafe.pdf) |
| 2024-08-14 | [Results- Financial Results For 30Th June, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=52a45cd3-a5d0-4454-a131-6172a791ac4f.pdf) |
| 2024-05-30 | [Results For The Financial Year Ended 31St March 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3f506acb-38de-41cc-b2dd-cc2e9dc4bd98.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 9 Feb - Read with Para A and Part A of schedule III of the said regulations, please find enclosed herewith the details of scheduled Meeting(s) between the … | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 9 Feb - Read with Para A and Part A of schedule III of the said regulations, please find enclosed herewith the details of scheduled Meeting(s) between the …](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0d8f921e-7ae2-4e77-b15f-8abee88a16e2.pdf) |
| 5h - Virtual one-on-one meeting with Motilal Oswal on 16-Feb-2026; no UPSI or presentation. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 5h - Virtual one-on-one meeting with Motilal Oswal on 16-Feb-2026; no UPSI or presentation.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/0d3ecbd7-2eb5-4f7e-9451-8eaff0edf55e.pdf) |
| 4 Feb - Unaudited results for quarter and nine months ended 31-Dec-2025; limited review; ICC reconstituted 04-Feb-2026. | [Board Meeting Outcome for Outcome Of Board Meeting Dated 04.02.2026. 4 Feb - Unaudited results for quarter and nine months ended 31-Dec-2025; limited review; ICC reconstituted 04-Feb-2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/48dcb896-820b-4868-a0e2-e89cb9e9430b.pdf) |
| 4 Feb - Board approved unaudited Q3/9M (ended 31‑Dec‑2025) results; limited review; POSH ICC reconstituted effective 04‑Feb‑2026. | [Un-Audited Results For The Quarter And Nine Months Ended 31.12.2025. 4 Feb - Board approved unaudited Q3/9M (ended 31‑Dec‑2025) results; limited review; POSH ICC reconstituted effective 04‑Feb‑2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f1e823da-80e2-4519-9e48-3d18d3ab06c0.pdf) |
| 30 Jan - Board meeting on 04 Feb 2026 to consider unaudited results for quarter ended 31 Dec 2025. | [Board Meeting Intimation for 1. Un-Audited Financial Results For The Quarter Ended December 31, 2025. 2. Limited Review Report For The Quarter Ended December 31, 2025. 3. Any Other Business With The Permission Of The Chair. 30 Jan - Board meeting on 04 Feb 2026 to consider unaudited results for quarter ended 31 Dec 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/25b84f05-9fdd-4b3b-9b55-1cf1a5b31c52.pdf) |
| 3 Mar - Dixon invested INR7.39 Cr, Longcheer INR2.60 Cr; JV consummated 3 Mar 2026; Dixon holds 74%. | [Announcement under Regulation 30 (LODR)-Acquisition 3 Mar - Dixon invested INR7.39 Cr, Longcheer INR2.60 Cr; JV consummated 3 Mar 2026; Dixon holds 74%.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f557188c-8e03-49e1-a183-df552018af68.pdf) |
| 27 Feb - Virtual one-on-one meetings with Motilal Oswal and JP Morgan on 26 Feb 2026; no price-sensitive information. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 27 Feb - Virtual one-on-one meetings with Motilal Oswal and JP Morgan on 26 Feb 2026; no price-sensitive information.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/122d52e3-2574-4c31-9bae-e2d3e1d886bc.pdf) |
| 27 Feb - CFC Finlease assigned ESG Rating 75 to Dixon on Feb 27, 2026; assignment independent. | [Announcement Under Regulation 30 Of SEBI LODR- ESG Rating By CFC Finlease Private Limited 27 Feb - CFC Finlease assigned ESG Rating 75 to Dixon on Feb 27, 2026; assignment independent.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/144c6d01-3577-4178-a0d8-c19b9a7a5db7.pdf) |
| 27 Apr - Oxygenta says it is not a Large Corporate; initial disclosure not applicable for FY2026-27. | [Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A 27 Apr - Oxygenta says it is not a Large Corporate; initial disclosure not applicable for FY2026-27.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/87fad55c-3603-49eb-adf6-717a241eb911.pdf) |
| 27 Apr - Oxygenta Pharma says it is not a Large Corporate; FY2025-26 debt borrowing nil. | [Format of the Annual Disclosure to be made by an entity identified as a LC - Annexure B2 27 Apr - Oxygenta Pharma says it is not a Large Corporate; FY2025-26 debt borrowing nil.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/9d196d12-a528-46de-b689-15cca5a9db32.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Oct 2025 | [Concall - Oct 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/95dbb3ac-5662-4cd9-a145-78effb6c373c.pdf) |
| Oct 2024 | [Concall - Oct 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4c18ee5b-b6f4-4b8a-97b6-519950a55216.pdf) |
| Oct 2023 | [Concall - Oct 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1fe59f81-da6c-4088-9bc4-c6d7e9876f45.pdf) |
| Oct 2022 | [Concall - Oct 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ef44c44a-ac97-4e29-8245-06f8d59f0a2a.pdf) |
| May 2025 | [Concall - May 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/55e495a0-7626-4311-9f59-0a1b21076ca8.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/85178a76-e388-468a-8142-27d125947680.pdf) |
| May 2023 | [Concall - May 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/da60673a-fa9b-445a-b2cd-f8d813ef99ca.pdf) |
| Jun 2022 | [Concall - Jun 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1204ccfc-334c-4919-91f8-1b47fe7065bd.pdf) |
| Jul 2025 | [Concall - Jul 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/fe83e870-4ca3-462a-addd-5c85ec513959.pdf) |
| Jul 2024 | [Concall - Jul 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e81b87af-32ae-4439-a1d5-e34b735f8efe.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from bse | [Annual Report 2026 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/cddccb0e-0a8d-44a5-ade7-ce800035f359.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7eabc370-b827-435c-9dd2-8a70553a8062.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d68c1b96-07d7-4c55-bd5d-e7892f58e4c0.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/44312065-295c-4d01-ac79-338efd2f98f7.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1fd51f62-306e-4aa1-9407-db2ae30b30a6.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3d13c3c7-03c7-4af2-b0b6-2a6a1af5d417.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4280936c-9978-4130-b008-d904d6e9e158.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/540699/74024540699.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524636/76145524636.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/540699/71112540699.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:47:59.084Z.